Talecris Biotherapeutics, Inc. Company Profile
Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. (www.talecris.com)
News Articles
Return to top 50 pharma list Summary Website: Grifols Headquarters: Barcelona, Spain Ticker Symbol: GRF:Continuous SEC Link: Grifols SEC filings Subsidiaries: Araclon Biotech PlasmaCare Talecris B...
Smith & Nephew acquires Healthpoint Biotherapeutics for $782 million
Smith & Nephew has signed an agreement to acquire substantially all of the assets of Healthpoint Biotherapeutics for $782 million in cash. Healthpoint Biotherapeutics has been focused on biopharma...
Data from Eleven Biotherapeutics' EBI-005 preclinical study on ocular diseases
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (...
Valor, Oxygen Biotherapeutics enter License and Supply Agreement for Dermacyte
Oxygen Biotherapeutics, Inc., announced today that it has entered into a License and Supply Agreement with the Cosmetics Division of Valor SA of Lausanne, Switzerland, for Dermacyte, a perfluorocarbon...
[Northwest Biotherapeutics] nets $9.3mm through RDO
Cancer immunotherapeutics company [Northwest Biotherapeutics Inc.] netted $9.3mm through a registered direct offering. An undisclosed
How to select the best candidate for biotherapeutics drug development
Antibodies, antibody-like proteins, and other biotherapeutics represent a large and growing number of molecular entities entering human clinical trials in virtually all disease indications. The [...]
Menarini and Oxford BioTherapeutics ink $1 billion cancer pact
Menarini and Oxford BioTherapeutics announce a major innovative and strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer.The agreement covers five of antibody and a...
[Beat BioTherapeutics] gets seeded with $2.5mm
CET Capital Partners, the W Fund, and 19 other undisclosed investors have seeded gene therapy firm [Beat BioTherapeutics Corp.] with $2.5mm through the sale of debt. CET will contribute one board memb...
Drugs and Medications
Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]
Plasma Protein Fraction (Human) 5%, USPPlasmanate®
Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]
Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated
Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]
Albumin (Human) 5%, USPPlasbumin ®-5
Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]
Albumin (Human) 5%, USPPlasbumin ®-5
Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]
Albumin (Human) 20%, USPPlasbumin®-20
PubMed Articles
Biotherapeutics, including recombinant or plasma-derived human proteins and antibody-based molecules, have emerged as an important class of pharmaceuticals. Aggregation and immunogenicity are among th...
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration.
The subcutaneous (SC) route is of growing interest for the administration of biotherapeutics. Key products on the biotherapeutic market such as insulins, but also several immunoglobulins or Fc-fusion...
Subcutaneous administration of biotherapeutics: Current experience in animal models.
In recent years, many peptide- and protein-based biotherapeutics have been approved for subcutaneous (SC) delivery. The mechanisms and factors affecting the uptake and distribution of such large molec...
Protein Particulate Detection Issues in Biotherapeutics Development-Current Status.
Formation of aggregates and particulates in biopharmaceutical formulation continues to be one of the major quality concerns in biotherapeutics development. The presence of large quantities of aggregat...
An immune response to a biotherapeutic can be induced when the therapeutic is processed and presented by antigen presenting cell to T helper cells. This study evaluates the performance of an in vitro...
Clinical Trials
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...
Companies
Talecris Biotherapeutics Holdings Inc.
Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...
Talecris Biotherapeutics, Inc.
Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-th...
Talecris Biotherapeutics Holdings Corp.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disor...
Talecris Biotherapeutics is a new company proud to inherit a legacy of more than 60 years of providing lifesaving and life-enhancing plasma-derived therapeutic proteins. Through the assets of Bayer Bi...
More Information about "Talecris Biotherapeutics, Inc." on BioPortfolio
We have published hundreds of Talecris Biotherapeutics, Inc. news stories on BioPortfolio along with dozens of Talecris Biotherapeutics, Inc. Clinical Trials and PubMed Articles about Talecris Biotherapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Talecris Biotherapeutics, Inc. Companies in our database. You can also find out about relevant Talecris Biotherapeutics, Inc. Drugs and Medications on this site too.
